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SUMMARY
This study aimed to estimate the prevalence and risk factors for Hepatitis C Virus (HCV) infection 
in Mexican Americans living in South Texas. We tested plasma for the presence of HCV antibody 
from the Cameron County Hispanic Cohort (CCHC), a randomized, population-based cohort in an 
economically disadvantaged Mexican-American community on the United States/Mexico border 
with high rates of chronic disease. A weighted prevalence of HCV antibody of 2.3% (n=1131, 
95% CI 1.2%–3.4%) was found. Participants with diabetes had low rates of HCV antibody (0.4%, 
95% CI 0.0%–0.9%) and logistic regression revealed a statistically significant negative association 
between HCV and diabetes (OR 0.20 95% CI 0.05–0.77) after adjusting for sociodemographic and 
clinical factors. This conflicts with reported positive associations of diabetes and HCV infection. 
No classic risk factors were identified, but important differences between genders emerged in 
analysis. This population-based study of HCV in Mexican-Americans suggests that national 
studies do not adequately describe the epidemiology of HCV in this border community and that 
unique risk factors may be involved.
INTRODUCTION
Hepatitis C Virus (HCV) is one of the main causes of chronic viral hepatitis [1]. Worldwide, 
the estimated prevalence of HCV is 2.2%, or about 130 million people [2]. In the United 
States (US), the prevalence has been decreasing since 1992, from 2.4% to approximately 
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1.6%, where it has remained relatively stable since 2006 [3,4]. While the acute phase of 
HCV infection is not typically life-threatening, complications associated with chronic HCV 
– fibrosis, cirrhosis, and hepatocellular carcinoma – carry a poor prognosis and represent a 
significant societal and financial burden [5–7].
Despite the identification of HCV over 25 years ago, data on HCV epidemiology in minority 
groups are sparse [8]. It has been established, largely through the National Health and 
Nutrition Examination Survey (NHANES), that racial and ethnic disparities in HCV 
epidemiology exist, but little is known about prevalence in communities with the greatest 
health disparities, particularly those along the US/Mexico Border. Currently, passive 
surveillance of HCV infection is inadequate to estimate prevalence [9], so randomized 
population-based seroprevalence studies are a practical way to estimate the prevalence of 
HCV in particular communities in the US.
To our knowledge, there are two data sources that have stratified HCV epidemiology in US 
Hispanics by ethnic subgroup. Kuniholm and co-workers used NHANES data to conduct 
stratified analysis of HCV epidemiology, comparing Mexican Americans to “other 
Hispanic”. These data suggest that Mexican American Hispanics may have a decreased risk 
of HCV compared with non-Mexican Hispanics [8]. These data were supplemented using 
the Hispanic Community Health Study/Study of Latinos (HCHS/SOL), which recruited 
urban Hispanic/Latino participants from the Bronx, Miami, Chicago, and San Diego to 
participate in HCV research [8]. They found that Hispanics constitute a strikingly 
heterogeneous group in HCV epidemiology, with anti-HCV prevalence among Mexican 
Americans (1.9%; 95% CI 1.1–3.4) falling between the low prevalence seen in South 
American Hispanics (0.4%; 95% CI 0.1–1.9) and the high prevalence seen in Puerto Rican 
Hispanics (11.6%; 95% CI 9.4–14.1) [8]. However, we have previously shown that national 
studies such as HCHS/SOL tend to underestimate the burden of disease in Mexican 
Americans in Cameron County, TX [10,11], and we sought to validate national Mexican 
American HCV prevalence studies in a discrete, homogenous population of Mexican 
Americans with high rates of obesity, diabetes, and other chronic disease [12]. Further, since 
we have previously observed high rates of cirrhosis with no known etiology in Cameron 
County [11], it is urgent to fully characterize the unique risk factors and causes of chronic 
liver disease in this Mexican American community on the US-Mexico border.
METHODS
This study aimed to estimate the prevalence of, and determine the risk factors for, HCV in 
Mexican Americans in Cameron County, Texas, using data from a population-based cohort 
study, the Cameron County Hispanic Cohort (CCHC; n=3300). This is a ‘Framingham-like’ 
cohort of a Mexican-American community, recruited from households, active since 2004 
[13]. Households are stratified by socioeconomic strata and randomly selected by census 
tract/block; all occupants 18 years or older are invited to participate. Participants then visit 
our Clinical Research Unit, where extensive sociodemographic, clinical, and laboratory data 
are collected, and are followed-up at five year intervals [12]. In the present work, we 
designed a cross-sectional study of baseline data, accessing archived plasma samples from 
the CCHC. Plasma samples were selected sequentially, beginning with the first participant in 
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the CCHC, thus preserving the two-stage sampling design. The study was approved by the 
Committee for the Protection of Human Subjects of the University of Texas Health Science 
Center at Houston as HSC-SPH-03-007-B.
We tested 1331 samples for the presence of Hepatitis C Antibody (anti-HCV) using the 
ORTHO® HCV Version 3.0 Test system (Ortho-Clinical Diagnostics, Raritan, NJ). Plates 
were read in a Spectramax M5 spectrophotometer (Molecular Devices, Sunnyvale, CA) at a 
wavelength of 490 nm with a reference wavelength of 620 nm. Reactive and non-reactive 
results were determined according to manufacturer’s specification. Results were then 
merged with the existing CCHC database for analysis.
Definitions
Any participant with a positive HCV antibody assay was considered to be in the HCV group. 
In analysing diabetes mellitus (DM) results, “diabetes status” was categorised into three 
groups in accordance with the American Diabetes Association’s 2010 diagnostic criteria: 
normal, Impaired Fasting Glucose (hereafter “pre-diabetes”) and diabetic (hereafter, “DM”) 
[14]. We considered participants to have a history of smoking if they had smoked more than 
100 cigarettes in their life, and considered “alcohol consumption” to be any participant that 
drinks at least occasionally (compared to not at all). Finally, when discussing liver function 
tests (LFTs), we refer only to alanine transaminase (ALT) and aspartate aminotransferase 
(AST) levels.
Statistical Methods
We conducted design-based analyses using age- and gender-adjusted sampling weights to 
scale the sample to the population and also accounted for the potential clustering effect 
among participants from the same household. For descriptive purposes of the sample, 
categorical variables for demographic and clinical characteristics were summarized in 
unweighted frequencies and weighted percentages, and continuous variables for 
demographic and clinical characteristics were summarized using weighted means and their 
standard errors. Among participants with HCV, we counted the number who reported taking 
any of the commonly prescribed anti-HCV medications in the US and Mexico 
(peginterferon, ribavirin, and protease inhibitors, or any of their marketed names – including 
generics – in English and Spanish). Design-adjusted, weighted prevalence of HCV was 
calculated and analyses were conducted for various risk factors 1) in the entire sample and 
2) in the sample stratified by gender. The Rao-Scott design-adjusted χ2 test was used to test 
for equality of proportions across the risk factors groups. Odds ratios with 95% Wald 
Confidence Limits were reported for dichotomous categorical variables, and P-values were 
reported for non-dichotomous categorical variables. Univariable survey-weighted logistic 
regression analyses were performed to assess the effects of continuous variables on presence 
of HCV antibody.
Multivariable survey-weighted logistic regression analyses were performed to assess the 
independent effects of risk factors on HCV antibody detection, selected from the univariable 
analysis with moderate (P<0.10) association, in addition to demographic variables 
classically associated with HCV infection: age, gender, socioeconomic indicators, and 
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smoking and drinking history. Harmful multicollinearity effects between the independent 
variables of interest in the survey-weighted logistic regression multivariable model were not 
observed (VIF<1.5). Two-way multiplicative scale interaction effect between the 
independent variables were tested by including their product terms in the regression model 
and evaluating the Wald Chi-Square test statistics of their coefficient estimates. A two-sided 
test with P<0.05 was considered significant for all analyses. The survey-weighted logistic 
regression model fit was evaluated with F-adjusted mean residual goodness-of-fit test using 
Stata 13 (StataCorp. 2013. Stata Statistical Software: Release 13. College Station, TX: 
StataCorp LP). All other weighted analyses were conducted using SAS 9.4 (SAS Institute, 
Inc., Cary, North Carolina).
RESULTS
We tested a sample of the CCHC consisting of 1331 subjects for the presence of anti-HCV. 
Their average age was 48.7 years, and 40.7% were male. The sample did not differ 
significantly in age or gender from the cohort from which it was sampled. The majority 
(61.2%) were born in Mexico, 50.6% were overweight or obese, 26.3% had diabetes, and 
31.2% had abnormal LFTs (Table 1). Nearly half (46.8%) of those with diabetes had not 
been previously diagnosed (data not shown).
Thirty out of 1331 participants’ plasma tested positive for anti-HCV. This generated a 
weighted prevalence of 2.3% (95% CI 1.2%–3.4%).
A range of sociodemographic variables were tested for univariable association with HCV. 
Variables for gender, age, income, education level, nativity, and socioeconomic status had no 
significant association with HCV. Similarly, proxies for risky behavior (smoking history and 
alcohol consumption) did not yield significant associations.
In univariable analyses of clinical and biological variables, there was a significant 
association between the three categories of diabetes status (normal, pre-diabetes, DM) and 
HCV (P<0.005). The HCV rate was 0.4% (95% CI 0.0%–0.9%) among participants with 
DM, 4.0% (95% CI 1.6%–6.6%) among participants with pre-diabetes, and 1.1% (95% CI 
0.02%–2.2%) among normal participants. Elevated ALT and AST levels were significantly 
associated with HCV (OR 1.02 95% CI 1.00–1.03, and OR 1.03 95% CI 1.01–1.05, 
respectively) (Table 2). None of the participants with HCV reported taking any anti-HCV 
medication, and only 4 of 30 (12.2%, 95% CI 5.3–18.1) participants with HCV reported any 
history of viral hepatitis.
In gender-stratified univariable analysis, increased age was associated with HCV in females 
(OR 1.04 95% 1.01–1.06), but not in males. The average age of women with HCV was 
significantly higher than the average age of men with HCV (57.4 vs 44.5, P<0.005). Further, 
there was a significant association between diabetes classification and HCV in females 
(P<0.005), with an HCV prevalence of 0.6% (95% CI 0%–1.3%) among participants with 
DM, 4.4% (95% CI 1.5%-7.3%) among participants with pre-diabetes, and 1.1% (95% CI 
0.02%-2.2%) among normal participants. The association was not significant in males 
(P=0.1765). A history of smoking was significantly associated with HCV in males (OR 5.3 
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95% CI 1.1–25.1), but not in females. Alcohol consumption in males had a significant 
positive association with HCV (OR 15.2 95% CI 1.8,130.5), and a significant negative 
association with HCV among females (OR 0.2 95% CI 0.1–0.7). Finally, ALT and AST 
levels were associated with HCV in females (OR 1.03 95% CI 1.01,1.05, OR 1.05 95% CI 
1.02,1.07, respectively), but not in males (Table 3).
In the regression analysis, DM (compared to “normal”) was independently negatively 
associated with HCV (OR 0.20 95% CI 0.05–0.77) after controlling for age, gender, 
socioeconomic quartile, employment status, obesity, ALT and AST levels, and smoking and 
drinking history. Pre-diabetes was not significantly associated with HCV (compared to 
“normal”). No other significant effects emerged in the model, and no interaction effects were 
found to contribute significantly to the fit of the model (Table 4). As an alternative analysis, 
we ran the same regression, but used DM as the reference value instead of “normal”. Here, 
pre-diabetes (compared to DM) was significantly positively associated with HCV (OR 8.93 
95% CI 2.48–32.15), as was “normal” (compared to DM) (OR 5.30 95% CI 1.30–21.54) 
(data not shown).
DISCUSSION
The Centers for Disease Control and Prevention (CDC) estimate that there were 16,000 new 
cases of HCV in the US in 2009 [15], most of which will go undiagnosed and many of 
which will progress to chronic infection. Klevens and co-workers consider injection drug 
users to be the “center of the current hepatitis C epidemic” [4]. There are few data on 
injection drug use in the US/Mexico border region, although one population-based study 
showed that the lifetime prevalence of injection drug use is low (1.0%) in Cameron County 
[16].
The prevalence of HCV in this population (2.3%) is similar to the national population-based 
rate found in Mexican Americans in NHANES (2.1%) and HCHC/SOL (1.9%) [8]. This 
community differs from previous studies of HCV in Mexican Americans, however. First, the 
region is dominated by the Brownsville metropolitan area (population 400,000, 85% 
Mexican American), a network of small cities and towns on the US/Mexico Border, 
considered among the poorest in the US [17–19]. As such, this is not a scattered urban 
population sample like that in HCHC/SOL, but rather a single non-urban population. It is 
also tightly integrated with Matamoros, Tamaulipas, Mexico, so it was important to consider 
the prevalence of HCV in northern Mexico. It is thought that the nationwide prevalence of 
HCV in Mexico is lower (1.0%–1.4%) than in the US [20,21], but that the northern Mexican 
states have a slightly higher rate at 1.7% [22]. It therefore appears that the rate of HCV in 
Cameron County is slightly higher than the rate in northern Mexico, and similar to that of 
Mexican Americans in the US.
We have previously quantified poor health outcomes and high rates of undiagnosed chronic 
disease in Cameron County. For instance, the prevalence of DM is 30.7% (49.7% 
undiagnosed), hypercholesterolemia, 48.2% (48.7% undiagnosed) and hypertension, 30.5% 
(16% undiagnosed) [12]. In the present study, at least 87.8% of those with HCV had no 
known history of viral hepatitis. For comparison, current national estimates suggest that 
WATT et al. Page 5













between 50% and 75% of those infected with HCV are unaware of their infection [23]. This 
suggests that HCV may be more often undiagnosed, and therefore untreated, in Cameron 
County than in the rest of the country. This is not surprising, considering 65.1% of the 
CCHC has no insurance of any kind, and the rates of undiagnosed chronic disease are high 
[10–12].
It is surprising that certain risk factors seen in previous HCV studies did not emerge in this 
work. We hypothesized that the risk factors seen in HCHS/SOL (male gender and US 
nativity, for instance) would present in our data, but there were no significant associations 
with these variables. In gender-stratified analysis, there were several associations – marital 
status, age, ALT levels, and AST levels – that emerged only in females. This is partially 
attributable to the low unweighted sample size of males (n=393), which limited statistical 
power for gender-stratified tests. It also suggests that significant epidemiological differences 
between men and women in this cohort exist. For example, the proportion of male 
participants with abnormal LFTs is significantly higher than the proportion of female 
participants with abnormal LFTs (38.6% vs. 26.1%, P<0.005).
Most striking, however, was the strong negative association between DM and HCV. As 
shown, the prevalence of HCV was highest among those with pre-diabetes, and lowest 
among those with DM. While we do not propose that diabetes is protective, per se, for HCV 
in this population, our results do indicate a negative association between HCV and DM, even 
after controlling for a variety of sociodemographic and clinical factors. There is considerable 
controversy surrounding this relationship, as many researchers have previously found 
positive associations between DM and HCV. There is both epidemiological [24,25] and 
direct experimental evidence [26] that suggests that DM may predispose HCV infection, and 
that HCV might play a role in the progression of DM, although these interactions have been 
contested [27,28]. In one systematic review of this association, researchers found 45 out of 
46 studies proposed a positive association between DM and HCV [29]. On the other hand, 
there are two studies that report a result of low prevalence of HCV among diabetics [27,30], 
although these studies were not population-based and do not account for ascertainment bias. 
More recently, Ruhl and coworkers, using NHANES data, were unable to demonstrate a 
relationship between DM and HCV [28]. Instead, the authors suggest that elevated liver 
enzymes had a non-negligible effect on the association between DM and HCV [28]. In the 
present work, we have shown that DM is independently negatively associated with HCV 
even when controlling for ALT and AST. The widely varying prevalence of HCV among the 
three categories of DM, and the result of an independent effect of DM status on HCV in 
multivariable regression modeling, together suggest an important association in this 
population. The literature on this association, however, especially the recent work by Ruhl 
and co-workers using NHANES, urges caution in interpreting these findings, and further 
study is needed to examine the effect of liver enzymes on this association.
Additionally, there are important differences between the CCHC and NHANES, although 
both are population-based cohort studies. This is an ethnically homogenous study 
population, which allows for detailed analysis of Mexican Americans in particular, whereas 
NHANES samples from a heterogeneous national population. Other distinctions between 
this study and the recent NHANES work are that the prevalence of diabetes is much higher 
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in this cohort (26.8% vs 10.5%), and this study is community-based, rather than national. 
These differences, especially the much higher prevalence of diabetes in Cameron County, 
allow for the possibility of a DM-HCV association that is present in this community but not 
detectable at the national level.
The high rate of HCV among those with pre-diabetes (4.0%) is cause for some concern. 
Obesity, insulin resistance, and diabetes are associated with a more rapid progression of 
fibrosis in HCV-infected individuals [31–33]. Higher levels of insulin resistance are also 
associated with a poorer response to antiviral therapy for HCV [34]. And, because this 
community suffers high rates of insulin resistance [35], diabetes, obesity, and all-cause liver 
disease, it may be prudent to incorporate HCV screening efforts into pre-diabetes and DM 
education and outreach already in place.
Finally, there were some limitations to this study. This cohort does not contain data on risky 
behavior (such as illicit drug use, risky sexual practices, tattoos, or unhygienic medical 
procedures), which are often significant in HCV epidemiology. Despite this, the CCHC 
provides the only available large population-based data on community-dwelling Mexican 
Americans in the country, and the present study has effectively shown that the epidemiology 
of HCV in this population differs from that of existing national studies. Second, an anti-
HCV assay does not provide data on the burden of active disease, and as such the burden of 
acute or chronic HCV remains unknown in this region. Using an HCV antibody test, 
however, allowed us to compare prevalence estimates with other studies, like NHANES and 
HCHS/SOL, which also used anti-HCV to estimate prevalence.
In conclusion, this study may be seen as preliminary work in understanding the unique 
epidemiology of HCV in a border-dwelling Mexican American community with severe 
health disparities. Our results – particularly the low prevalence of HCV in participants with 
diabetes, despite overall elevated prevalence of HCV and rampant diabetes – contrast with a 
large body of previous work. Moving forward, it will be important (1) to explore risk factors 
for HCV exposure unique to Cameron County, and (2) to determine the genotype and 
seroprevalence of HCV RNA, to characterize the burden of active disease in this community. 
We have shown, much like previous studies, that diabetes is an important consideration in 
the epidemiology of HCV. In a Mexican American population with high prevalence of 
diabetes, obesity, and non-alcoholic liver disease, it is critical to characterise any factors, 
such as chronic viral hepatitis, that might further insult the health of the liver.
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Table 1






Place of Birth, n (%)
Mexico 908 (61.2)
United States 407 (37.1)
Other 16 (1.7)













Age, meang (SE) 48.7 (0.8)
Household Income, meang (SE) 21,433 (1462.4)
Years Pre-College Education, meang (SE) 7.4 (0.3)
Abbreviations: LFT, Liver Function Test; SE, standard error
a
 All frequencies reflect unweighted data
b
 All percentages reflect weighted data
c
 Includes any type of public or private health coverage
d
 Defined as Body Mass Index ≥ 30
e
 Defined as abnormal alanine transaminase or abnormal aspartate aminotransferase levels
f
 According to the 2010 Diagnostic Criteria of the American Diabetes Association
g
 Weighted mean













WATT et al. Page 11
Table 2
Weighted univariable analysis of HCV by categorical and continuous variables, Cameron County Hispanic 
Cohort (2004–2012)
Variable Levels HCV/total (%)a OR (95% CI)
Gender
Female 18/938 (1.7) Reference
Male 12/393 (2.8) 1.4 (0.6,3.6)
Marital Status
Unmarried 15/533 (2.6) Reference
Married 15/794 (2.1) 0.8 (0.3,2.0)
Socioeconomic Status
Lower 50% 16/580 (2.9) Reference
Upper 50% 14/751 (1.8) 0.6 (0.2,1.7)
Obese
No (BMI<30) 16/651 (2.7) Reference
Yes (BMI≥30) 14/680 (1.9) 0.7 (0.3,1.7)
School
≤8 years 12/520 (2.2) Reference
>8 years 18/809 (2.4) 1.1 (0.5,2.6)
Finished High School
No 20/755 (2.4) Reference
Yes 10/574 (2.2) 0.9 (0.3,2.5)
Majority School Years
Mexico 22/837 (2.7) Reference
US 8/438 (2.0) 0.7 (0.2,2.3)
Diabetesb




Yes 8/401 (2.9) Reference
No 22/929 (2.0) 0.7 (0.3,1.8)
Employment Status
Employed 17/640 (2.8) Reference
Not employed 13/691 (1.8) 0.6 (0.2,1.6)
History of Smokingd
No 20/963 (1.8) Reference
Yes 10/368 (3.5) 2.0 (0.8,5.2)
Alcohol Consumption
No 16/705 (2.1) Reference
Yes 14/626 (2.4) 1.1 (0.4,2.6)
Age (years)e 48.7 (0.8) 1.0 (0.99,1.03)
Years in Cameron Countye 24.6 (1.0) 0.99 (0.98, 1.01)
Years of Pre-College Educatione 7.4 (0.3) 1.04 (0.93, 1.15)
ALTf (u/L)e 40.9 (1.0) 1.02 (1.00,1.03)*
ASTf (u/L)e 35.1 (0.9) 1.03 (1.01,1.05)*
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Abbreviations: OR, Odds Ratio; CI, Confidence Interval; BMI, Body Mass Index; ALT, Alanine Transaminase; AST, Aspartate Aminotransferase; 
SE, Standard Error
*
Statistically significant with P<0.05
a
 All Percentages Weighted
b
 According to the 2010 Diagnostic Criteria of the American Diabetes Association
c
 Includes any type of public or private health coverage
d
 Defined as ever having smoked more than 100 cigarettes
e
 Continuous variable: mean (SE) and OR (95% Wald CI) estimates are given
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Table 4
Multivariable logistic regression analysis of predictors of anti-HCV in serum, Cameron County Hispanic 
Cohort (2004–2012)
Variable OR (95% CI)
Male Gender 0.85 (0.43,1.70)
Increased Agea 1.02 (1.00,1.05)
Higher SES 0.64 (0.23,1.78)
Unemployed 0.76 (0.27,2.12)
Obeseb 0.67 (0.22,2.07)
ALT (u/L)a 1.01 (0.99,1.03)
AST (u/L)a 1.02 (0.99,1.05)
Alcohol Consumption 0.78 (0.43,1.40)
Smoking Historyc 2.36 (0.98,5.68)
Diabetesd,e 0.20 (0.05,0.77)*
Pre-Diabetese,f 1.69 (0.55,5.14)
Abbreviations: OR, Odds Ratio; CI, Confidence Interval; SES, Socioeconomic Status; ALT, alanine aminotransferase; AST aspartate transaminase
*




 Defined as Body Mass Index ≥ 30
c
 Defined as ever having smoked more than 100 cigarettes
d
 According to the 2010 Diagnostic Criteria of the American Diabetes Association
e
 Compared to non-diabetic, non-impaired fasting glucose
f
 According to the 2010 Criteria of the American Diabetes Association, definition for “impaired fasting glucose”
Epidemiol Infect. Author manuscript; available in PMC 2016 September 07.
